{"id":39627,"date":"2026-09-28T11:19:29","date_gmt":"2026-09-28T11:19:29","guid":{"rendered":"https:\/\/itbusinesstoday.com\/?p=39627"},"modified":"2026-09-28T11:19:29","modified_gmt":"2026-09-28T11:19:29","slug":"itm-and-lumara-bio-share-new-itm-11-cancer-therapy-information","status":"publish","type":"post","link":"https:\/\/itbusinesstoday.com\/ja\/health-tech\/itm-and-lumara-bio-share-new-itm-11-cancer-therapy-information\/","title":{"rendered":"ITM\u3068Lumara Bio\u3001ITM-11\u306b\u3088\u308b\u304c\u3093\u6cbb\u7642\u306b\u95a2\u3059\u308b\u65b0\u305f\u306a\u60c5\u5831\u3092\u516c\u8868\u3057\u305f"},"content":{"rendered":"

ITM Isotope Technologies Munich SE\uff08ITM\uff09\u304a\u3088\u3073\u305d\u306e\u816b\u760d\u6cbb\u7642\u90e8\u9580\u3001, Lumara Bio<\/a> have shared clinical information about their experimental radiopharmaceutical, ¹⁷⁷Lu-edotreotide (ITM-11) for patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The information was shared at the 2026 American Society for Radiation Oncology (ASTRO) Annual Meeting in Boston. The focus was on what happens when patients get treatment and how radiation is spread in the body during this targeted therapy.<\/p>

\u3053\u306e\u60c5\u5831\u306b\u306f\u3001SwissNET\u30ec\u30b8\u30b9\u30c8\u30ea\u306e\u30c7\u30fc\u30bf\u304a\u3088\u3073\u7b2c3\u76f8COMPETE\u8a66\u9a13\u306e\u4e00\u90e8\u3092\u7528\u3044\u3066\u5b9f\u65bd\u3055\u308c\u305f\u7814\u7a76\u306e\u7d50\u679c\u304c\u542b\u307e\u308c\u3066\u3044\u308b\u3002\u3053\u308c\u3089\u306e\u7d50\u679c\u306f\u3001\u795e\u7d4c\u5185\u5206\u6ccc\u816b\u760d\u306e\u60a3\u8005\u306b\u5bfe\u3057\u3066\u3001\u6a19\u7684\u653e\u5c04\u6027\u533b\u85ac\u54c1\u7642\u6cd5\u304c\u3069\u306e\u3088\u3046\u306b\u7528\u3044\u3089\u308c\u308b\u53ef\u80fd\u6027\u304c\u3042\u308b\u304b\u306b\u3064\u3044\u3066\u306e\u77e5\u898b\u3092\u52a0\u3048\u308b\u3082\u306e\u3067\u3042\u308b\u3002\u305f\u3060\u3057\u3001ITM-11\u306f\u73fe\u5728\u3082\u958b\u767a\u4e2d\u3067\u3042\u308a\u3001\u3044\u304b\u306a\u308b\u4fdd\u5065\u5f53\u5c40\u304b\u3089\u3082\u627f\u8a8d\u3055\u308c\u3066\u3044\u306a\u3044\u3002.<\/p>

SwissNET\u30ec\u30b8\u30b9\u30c8\u30ea\u7814\u7a76\u304c\u60a3\u8005\u306e\u6cbb\u7642\u6cd5\u3092\u691c\u8a3c\u3059\u308b<\/h3>

The first study shared information about what happened to 49 adults with advanced well-differentiated somatostatin receptor-positive neuroendocrine tumors. These patients had gotten worse at 12 months after their first round of ¹⁷⁷Lu-edotreotide.<\/p>

Of the 49 people in the study 37 got treatment with ¹⁷⁷Lu-edotreotide. The other 12 got a kind of treatment that is not a radiopharmaceutical.<\/p>

\u3053\u306e\u7814\u7a76\u306b\u3088\u308b\u3068\u3001\u6cbb\u7642\u3092\u53d7\u3051\u305f\u4eba\u3005\u306e\u75c5\u72b6\u304c\u60aa\u5316\u3059\u308b\u307e\u3067\u306e\u671f\u9593\u306f\u3001\u4e2d\u592e\u5024\u306712.5\u30f6\u6708\u3060\u3063\u305f\u3002 \u6cbb\u7642\u3092\u53d7\u3051\u305f\u4eba\u3005\u306e\u751f\u5b58\u671f\u9593\u306e\u4e2d\u592e\u5024\u306f4.8\u30f6\u6708\u3060\u3063\u305f\u3002\u6cbb\u7642\u3092\u53d7\u3051\u305f\u4eba\u3005\u306e\u5e73\u5747\u751f\u5b58\u671f\u9593\u306f90.1\u30f6\u6708\u3060\u3063\u305f\u3002\u6cbb\u7642\u3092\u53d7\u3051\u306a\u304b\u3063\u305f\u4eba\u3005\u3067\u306f39.8\u30f6\u6708\u3060\u3063\u305f\u3002\u6570\u5024\u304b\u3089\u898b\u308b\u3068\u3001\u8a8d\u3081\u3089\u308c\u305f\u5dee\u306f\u6709\u610f\u306a\u3082\u306e\u3060\u3063\u305f\u3002.<\/p>

\u3053\u306e\u7d50\u679c\u306f\u3001\u6cbb\u7642\u5f8c\u306b\u75c5\u72b6\u304c\u60aa\u5316\u3057\u305f\u4e00\u90e8\u306e\u60a3\u8005\u306b\u3064\u3044\u3066\u306f\u3001\u3055\u3089\u306a\u308b\u6cbb\u7642\u3092\u691c\u8a0e\u3059\u308b\u4fa1\u5024\u304c\u3042\u308b\u304b\u3082\u3057\u308c\u306a\u3044\u3053\u3068\u3092\u793a\u5506\u3057\u3066\u3044\u308b\u3002\u305f\u3060\u3057\u3001\u3053\u306e\u7814\u7a76\u306f\u4e8b\u5f8c\u7684\u306b\u884c\u308f\u308c\u305f\u3082\u306e\u3067\u3042\u308a\u3001\u5bfe\u7167\u7fa4\u306e\u4eba\u6570\u3082\u5c11\u306a\u304b\u3063\u305f\u305f\u3081\u3001\u751f\u5b58\u671f\u9593\u306e\u5dee\u304c\u3055\u3089\u306a\u308b\u6cbb\u7642\u306b\u3088\u308b\u3082\u306e\u3067\u3042\u308b\u3053\u3068\u3092\u8a3c\u660e\u3059\u308b\u3082\u306e\u3067\u306f\u306a\u3044\u3002.<\/p>

COMPETE\u8a66\u9a13\u304c\u653e\u5c04\u7dda\u7dda\u91cf\u306b\u95a2\u3059\u308b\u77e5\u898b\u3092\u3082\u305f\u3089\u3059<\/h3>

The presentation focused on dosimetry results from Substudy A of the Phase 3 COMPETE trial, which is assessing ¹⁷⁷Lu-edotreotide in patients with GEP‑NETs.<\/p>

\u3053\u306e\u5206\u6790\u3067\u306f\u300117\u4eba\u306e\u60a3\u8005\u306e\u81d3\u5668\u306b\u5230\u9054\u3057\u305f\u653e\u5c04\u7dda\u5438\u53ce\u7dda\u91cf\u3092\u6e2c\u5b9a\u3059\u308b\u3068\u3068\u3082\u306b\u30019\u4eba\u306e\u60a3\u8005\u306e17\u304b\u6240\u306e\u816b\u760d\u75c5\u5909\u306b\u5230\u9054\u3057\u305f\u7dda\u91cf\u3082\u6e2c\u5b9a\u3057\u305f\u3002\u305d\u306e\u7d50\u679c\u3001\u816b\u760d\u306e\u653e\u5c04\u7dda\u5438\u53ce\u7dda\u91cf\u306f\u3001\u81d3\u5668\u304c\u53d7\u3051\u305f\u7dda\u91cf\u3088\u308a\u3082\u9ad8\u3044\u3053\u3068\u304c\u660e\u3089\u304b\u306b\u306a\u3063\u305f\u3002.<\/p>

The kidney absorbed‑dose coefficients stayed fairly consistent showing a median variability of 14 percent. The analysis also discovered that the tumor‑to‑kidney absorbed‑dose coefficient ratios stayed above one throughout all treatment cycles which means that the radiation dose measured in tumors was higher than the dose measured in kidneys.<\/p>

These findings could help guide research into personalized dosimetry and treatment planning. The researchers also noted that the tumor absorbed‑dose coefficients declined over time a trend that has been seen before in studies of therapy.<\/p>

ITM-11\u304c\u795e\u7d4c\u5185\u5206\u6ccc\u816b\u760d\u306e\u6cbb\u7642\u306b\u3069\u306e\u3088\u3046\u306a\u610f\u5473\u3092\u6301\u3064\u306e\u304b<\/h3>

GEP‑NETs are a group of tumors that grow in cells of the gastrointestinal tract and pancreas. Treatment options often become more limited as the disease progresses after therapies.<\/p>

¹⁷⁷Lu‑edotreotide is a targeted radiopharmaceutical that is designed to deliver radiation to tumors that express somatostatin receptors. This approach falls under a treatment category called receptor radionuclide therapy or PRRT which uses a targeting molecule to carry a radioactive component directly to specific tumor cells.<\/p>

The new data contribute to the evidence that is being built around ITM‑11 and they include findings from the COMPETE trial. The Phase 3 study compared the therapy with everolimus in patients who have progressive, Grade 1 or Grade 2 GEP‑NETs. ITM is also testing the candidate in the Phase 3 COMPOSE study for patients who have aggressive, well‑differentiated GEP‑NETs.<\/p>

\u816b\u760d\u5b66\u754c\u306b\u3068\u3063\u3066\u3001\u3053\u308c\u3089\u306e\u77e5\u898b\u306f\u3001\u6a19\u7684\u3092\u7d5e\u3063\u305f\u653e\u5c04\u7dda\u7167\u5c04\u3001\u518d\u6cbb\u7642\u6226\u7565\u3001\u304a\u3088\u3073\u7dda\u91cf\u30e2\u30cb\u30bf\u30ea\u30f3\u30b0\u306b\u95a2\u3059\u308b\u7d99\u7d9a\u7684\u306a\u7814\u7a76\u306e\u91cd\u8981\u6027\u3092\u6d6e\u304d\u5f6b\u308a\u306b\u3057\u3066\u3044\u308b\u3002\u3053\u308c\u3089\u306e\u77e5\u898b\u3092\u81e8\u5e8a\u73fe\u5834\u3067\u3069\u306e\u3088\u3046\u306b\u5fdc\u7528\u3067\u304d\u308b\u304b\u3092\u5224\u65ad\u3059\u308b\u306b\u306f\u3001\u3055\u3089\u306a\u308b\u524d\u5411\u304d\u7814\u7a76\u304c\u5fc5\u8981\u3068\u306a\u308b\u3060\u308d\u3046\u3002.<\/p>

\u3053\u3061\u3089\u3082\u304a\u8aad\u307f\u304f\u3060\u3055\u3044\uff1a \u30a2\u30a4\u30aa\u30cb\u30b9\u793e\u3068\u30ed\u30b7\u30e5\u793e\u304c\u30bb\u30d5\u30a1\u30af\u30bb\u30eb\u30bb\u30f3\u306e\u958b\u767a\u9032\u6357\u3092\u5831\u544a\u3057\u305f<\/a><\/h4>

\u898f\u5236\u4e0a\u306e\u72b6\u6cc1\u3068\u4eca\u5f8c\u306e\u5bfe\u5fdc<\/h3>

ITM<\/a>-11\u306f\u6cbb\u7642\u6cd5\u3067\u3042\u308a\u3001\u898f\u5236\u5f53\u5c40\u304b\u3089\u7279\u5b9a\u306e\u7528\u9014\u306b\u3064\u3044\u3066\u627f\u8a8d\u3055\u308c\u3066\u3044\u306a\u3044\u3002ASTRO 2026\u3067\u306e\u767a\u8868\u306b\u306f\u81e8\u5e8a\u60c5\u5831\u304a\u3088\u3073\u7dda\u91cf\u6e2c\u5b9a\u60c5\u5831\u304c\u542b\u307e\u308c\u3066\u3044\u308b\u304c\u3001\u305d\u306e\u7d50\u679c\u306f\u65b0\u305f\u306a\u6cbb\u7642\u57fa\u6e96\u3092\u78ba\u7acb\u3059\u308b\u3082\u306e\u3067\u306f\u306a\u3044\u3002.<\/p>

\u7814\u7a76\u304c\u9032\u3080\u306b\u3064\u308c\u3001\u3069\u306e\u60a3\u8005\u304c\u6cbb\u7642\u306e\u6069\u6075\u3092\u53d7\u3051\u3089\u308c\u308b\u304b\u3001\u653e\u5c04\u7dda\u91cf\u3092\u60a3\u8005\u3054\u3068\u306b\u3069\u306e\u3088\u3046\u306b\u8abf\u6574\u3067\u304d\u308b\u304b\u3001\u305d\u3057\u3066\u3053\u306e\u6cbb\u7642\u6cd5\u304c\u4ed6\u306e\u5229\u7528\u53ef\u80fd\u306a\u9078\u629e\u80a2\u3068\u6bd4\u3079\u3066\u3069\u3046\u8a55\u4fa1\u3055\u308c\u308b\u304b\u3092\u7406\u89e3\u3059\u308b\u305f\u3081\u306b\u3001\u3055\u3089\u306a\u308b\u60c5\u5831\u304c\u5fc5\u8981\u3068\u306a\u308b\u3060\u308d\u3046\u3002.<\/p>","protected":false},"excerpt":{"rendered":"

ITM Isotope Technologies Munich SE (ITM) and its oncology therapeutics division, Lumara Bio have shared clinical information about their experimental radiopharmaceutical, ¹⁷⁷Lu-edotreotide (ITM-11) for patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The information was shared at the 2026 American Society for Radiation Oncology (ASTRO) Annual Meeting in Boston. The focus was on what happens when patients get treatment and how radiation is spread in the body during this targeted therapy.The information includes results from a study done using data from the SwissNET registry and a part of the Phase 3 COMPETE trial. These results add information about how targeted radiopharmaceutical therapy might be used for patients with neuroendocrine tumors. However ITM-11 […]<\/p>\n","protected":false},"author":7,"featured_media":39642,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_bbp_topic_count":0,"_bbp_reply_count":0,"_bbp_total_topic_count":0,"_bbp_total_reply_count":0,"_bbp_voice_count":0,"_bbp_anonymous_reply_count":0,"_bbp_topic_count_hidden":0,"_bbp_reply_count_hidden":0,"_bbp_forum_subforum_count":0,"wprm-recipe-roundup-name":"","wprm-recipe-roundup-description":"","postBodyCss":"","postBodyMargin":[],"postBodyPadding":[],"postBodyBackground":{"backgroundType":"classic","gradient":""},"footnotes":""},"categories":[89,8098],"tags":[10303,15949,15948,15946,15947],"ppma_author":[572],"class_list":["post-39627","post","type-post","status-publish","format-standard","has-post-thumbnail","category-health-tech","category-news-articles","tag-analysis","tag-itm","tag-lumara","tag-personalized-dosimetry","tag-therapy-information"],"yoast_head":"\nITM, Lumara Bio Present New ITM-11 Cancer Data<\/title>\n<meta name=\"description\" content=\"ITM and Lumara Bio provide updated ITM-11 data covering real-world retreatment and dosimetry results for GEP-NETs.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/itbusinesstoday.com\/ja\/health-tech\/itm-and-lumara-bio-share-new-itm-11-cancer-therapy-information\/\" \/>\n<meta property=\"og:locale\" content=\"ja_JP\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ITM, Lumara Bio Present New ITM-11 Cancer Data\" \/>\n<meta property=\"og:description\" content=\"ITM and Lumara Bio provide updated ITM-11 data covering real-world retreatment and dosimetry results for GEP-NETs.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/itbusinesstoday.com\/ja\/health-tech\/itm-and-lumara-bio-share-new-itm-11-cancer-therapy-information\/\" \/>\n<meta property=\"og:site_name\" content=\"itbusinesstoday\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-28T11:19:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2026\/09\/ITM-and-Lumara-Bio-Announce-Real-World-Re-treatment-Data-and-Dosimetry-Results-from-COMPETE-for-\u00b9\u2077\u2077Luedotreotide-ITM-11-in-GEP-NETs-at-ASTRO-2026-1.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"800\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"ITBT StaffWriter\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u57f7\u7b46\u8005\" \/>\n\t<meta name=\"twitter:data1\" content=\"ITBT StaffWriter\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593\" \/>\n\t<meta name=\"twitter:data2\" content=\"4\u5206\" \/>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ITM, Lumara Bio Present New ITM-11 Cancer Data","description":"ITM and Lumara Bio provide updated ITM-11 data covering real-world retreatment and dosimetry results for GEP-NETs.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/itbusinesstoday.com\/ja\/health-tech\/itm-and-lumara-bio-share-new-itm-11-cancer-therapy-information\/","og_locale":"ja_JP","og_type":"article","og_title":"ITM, Lumara Bio Present New ITM-11 Cancer Data","og_description":"ITM and Lumara Bio provide updated ITM-11 data covering real-world retreatment and dosimetry results for GEP-NETs.","og_url":"https:\/\/itbusinesstoday.com\/ja\/health-tech\/itm-and-lumara-bio-share-new-itm-11-cancer-therapy-information\/","og_site_name":"itbusinesstoday","article_published_time":"2026-09-28T11:19:29+00:00","og_image":[{"width":1200,"height":800,"url":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2026\/09\/ITM-and-Lumara-Bio-Announce-Real-World-Re-treatment-Data-and-Dosimetry-Results-from-COMPETE-for-\u00b9\u2077\u2077Luedotreotide-ITM-11-in-GEP-NETs-at-ASTRO-2026-1.webp","type":"image\/webp"}],"author":"ITBT StaffWriter","twitter_card":"summary_large_image","twitter_misc":{"\u57f7\u7b46\u8005":"ITBT StaffWriter","\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593":"4\u5206"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/itbusinesstoday.com\/health-tech\/itm-and-lumara-bio-share-new-itm-11-cancer-therapy-information\/#article","isPartOf":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/itm-and-lumara-bio-share-new-itm-11-cancer-therapy-information\/"},"author":{"name":"ITBT StaffWriter","@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#\/schema\/person\/94fb575e469aff25a4b938814d050f15"},"headline":"ITM and Lumara Bio Share New ITM-11 Cancer Therapy Information","datePublished":"2026-09-28T11:19:29+00:00","mainEntityOfPage":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/itm-and-lumara-bio-share-new-itm-11-cancer-therapy-information\/"},"wordCount":717,"publisher":{"@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#organization"},"image":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/itm-and-lumara-bio-share-new-itm-11-cancer-therapy-information\/#primaryimage"},"thumbnailUrl":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2026\/09\/ITM-and-Lumara-Bio-Announce-Real-World-Re-treatment-Data-and-Dosimetry-Results-from-COMPETE-for-\u00b9\u2077\u2077Luedotreotide-ITM-11-in-GEP-NETs-at-ASTRO-2026-1.webp","keywords":["Analysis","ITM","Lumara","personalized dosimetry","Therapy Information"],"articleSection":["Health Tech","News Articles"],"inLanguage":"ja"},{"@type":"WebPage","@id":"https:\/\/itbusinesstoday.com\/health-tech\/itm-and-lumara-bio-share-new-itm-11-cancer-therapy-information\/","url":"https:\/\/itbusinesstoday.com\/health-tech\/itm-and-lumara-bio-share-new-itm-11-cancer-therapy-information\/","name":"ITM, Lumara Bio Present New ITM-11 Cancer Data","isPartOf":{"@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#website"},"primaryImageOfPage":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/itm-and-lumara-bio-share-new-itm-11-cancer-therapy-information\/#primaryimage"},"image":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/itm-and-lumara-bio-share-new-itm-11-cancer-therapy-information\/#primaryimage"},"thumbnailUrl":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2026\/09\/ITM-and-Lumara-Bio-Announce-Real-World-Re-treatment-Data-and-Dosimetry-Results-from-COMPETE-for-\u00b9\u2077\u2077Luedotreotide-ITM-11-in-GEP-NETs-at-ASTRO-2026-1.webp","datePublished":"2026-09-28T11:19:29+00:00","description":"ITM and Lumara Bio provide updated ITM-11 data covering real-world retreatment and dosimetry results for GEP-NETs.","breadcrumb":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/itm-and-lumara-bio-share-new-itm-11-cancer-therapy-information\/#breadcrumb"},"inLanguage":"ja","potentialAction":[{"@type":"ReadAction","target":["https:\/\/itbusinesstoday.com\/health-tech\/itm-and-lumara-bio-share-new-itm-11-cancer-therapy-information\/"]}]},{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/itbusinesstoday.com\/health-tech\/itm-and-lumara-bio-share-new-itm-11-cancer-therapy-information\/#primaryimage","url":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2026\/09\/ITM-and-Lumara-Bio-Announce-Real-World-Re-treatment-Data-and-Dosimetry-Results-from-COMPETE-for-\u00b9\u2077\u2077Luedotreotide-ITM-11-in-GEP-NETs-at-ASTRO-2026-1.webp","contentUrl":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2026\/09\/ITM-and-Lumara-Bio-Announce-Real-World-Re-treatment-Data-and-Dosimetry-Results-from-COMPETE-for-\u00b9\u2077\u2077Luedotreotide-ITM-11-in-GEP-NETs-at-ASTRO-2026-1.webp","width":1200,"height":800,"caption":"ITM-and-Lumara"},{"@type":"BreadcrumbList","@id":"https:\/\/itbusinesstoday.com\/health-tech\/itm-and-lumara-bio-share-new-itm-11-cancer-therapy-information\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/itbusinesstoday.com\/"},{"@type":"ListItem","position":2,"name":"ITM and Lumara Bio Share New ITM-11 Cancer Therapy Information"}]},{"@type":"WebSite","@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#website","url":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/","name":"\u30a4\u30c3\u30c8\u30d3\u30b8\u30cd\u30b9\u30c8\u30a5\u30c7\u30a4","description":"","publisher":{"@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ja"},{"@type":"Organization","@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#organization","name":"\u30a4\u30c3\u30c8\u30d3\u30b8\u30cd\u30b9\u30c8\u30a5\u30c7\u30a4","url":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/","logo":{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#\/schema\/logo\/image\/","url":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/Asset-1.png","contentUrl":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/Asset-1.png","width":663,"height":275,"caption":"itbusinesstoday"},"image":{"@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#\/schema\/person\/94fb575e469aff25a4b938814d050f15","name":"ITBT\u30b9\u30bf\u30c3\u30d5\u30e9\u30a4\u30bf\u30fc","image":{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/Favicon-1.png90b3cb23d1d9c08733d969d29ea2d30d","url":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/Favicon-1.png","contentUrl":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/Favicon-1.png","caption":"ITBT StaffWriter"},"description":"ITBT\u30b9\u30bf\u30c3\u30d5\u30e9\u30a4\u30bf\u30fc\u306f\u3001IT Business Today\u306e\u793e\u5185\u5bc4\u7a3f\u8005\u3067\u3001\u30bf\u30a4\u30e0\u30ea\u30fc\u306a\u30cb\u30e5\u30fc\u30b9\u3068QuickBytes\u306e\u914d\u4fe1\u3092\u62c5\u5f53\u3057\u3066\u3044\u307e\u3059\u3002IT\u3001\u30cf\u30a4\u30c6\u30af\u3001\u4f01\u696d\u30bd\u30ea\u30e5\u30fc\u30b7\u30e7\u30f3\u306e\u6700\u65b0\u52d5\u5411\u3092\u30ab\u30d0\u30fc\u3057\u3001\u7c21\u6f54\u3067\u30a4\u30f3\u30d1\u30af\u30c8\u306e\u3042\u308b\u6700\u65b0\u60c5\u5831\u3092\u8aad\u8005\u306b\u63d0\u4f9b\u3057\u3066\u3044\u307e\u3059\u3002","sameAs":["https:\/\/itbusinesstoday.com\/"],"url":"https:\/\/itbusinesstoday.com\/ja\/author\/itbt-staffwriter\/"}]}},"authors":[{"term_id":572,"user_id":7,"is_guest":0,"slug":"itbt-staffwriter","display_name":"ITBT StaffWriter","avatar_url":{"url":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/Favicon-1.png","url2x":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/Favicon-1.png"},"author_category":"","first_name":"ITBT","last_name":"StaffWriter","user_url":"https:\/\/itbusinesstoday.com\/","job_title":"","description":"ITBT\u30b9\u30bf\u30c3\u30d5\u30e9\u30a4\u30bf\u30fc\u306f\u3001IT Business Today\u306e\u793e\u5185\u5bc4\u7a3f\u8005\u3067\u3001\u30bf\u30a4\u30e0\u30ea\u30fc\u306a\u30cb\u30e5\u30fc\u30b9\u3068QuickBytes\u306e\u914d\u4fe1\u3092\u62c5\u5f53\u3057\u3066\u3044\u307e\u3059\u3002IT\u3001\u30cf\u30a4\u30c6\u30af\u3001\u4f01\u696d\u30bd\u30ea\u30e5\u30fc\u30b7\u30e7\u30f3\u306e\u6700\u65b0\u52d5\u5411\u3092\u30ab\u30d0\u30fc\u3057\u3001\u7c21\u6f54\u3067\u30a4\u30f3\u30d1\u30af\u30c8\u306e\u3042\u308b\u6700\u65b0\u60c5\u5831\u3092\u8aad\u8005\u306b\u63d0\u4f9b\u3057\u3066\u3044\u307e\u3059\u3002"}],"_links":{"self":[{"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/posts\/39627","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/comments?post=39627"}],"version-history":[{"count":1,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/posts\/39627\/revisions"}],"predecessor-version":[{"id":39628,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/posts\/39627\/revisions\/39628"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/media\/39642"}],"wp:attachment":[{"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/media?parent=39627"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/categories?post=39627"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/tags?post=39627"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/ppma_author?post=39627"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}